logo

INM

InMed·NASDAQ
--
--(--)
--
--(--)
5.96 / 10
Netural

Corporate fundamentals rate mixed at 6.0/10. Beneficial factors: Days sales outstanding and Interest coverage ratio (EBIT / Interest expense) (%). Resultant assessment: balanced.

Fundamental(5.96)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value0.36
Score3/3
Weight16.49%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value7.50
Score2/3
Weight1.41%
1M Return1.11%
Days sales outstanding
Value29.79
Score2/3
Weight1.43%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight13.15%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.16%
1M Return8.45%
PB-ROE
Value-0.76
Score3/3
Weight17.83%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight-1.32%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value7.50
Score2/3
Weight0.54%
1M Return0.43%
Asset-MV
Value-0.23
Score3/3
Weight24.38%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight12.93%
1M Return8.41%
Is INM undervalued or overvalued?
  • INM scores 5.96/10 on fundamentals and holds a Fair valuation at present. Backed by its -13.80% ROE, -171.13% net margin, -0.32 P/E ratio, 0.23 P/B ratio, and 19.97% earnings growth, these metrics solidify its Netural investment rating.